Schwere bullöse arzneimittelinduzierte Hautreaktionen

Lernziel

Unter der Vielzahl von arzneimittelinduzierten Hautreaktionen finden sich verschiedene bullöse Reaktionsformen, deren klinische und ätiologische Einordnung selbst für erfahrene Dermatologen oft schwierig ist. Das frühzeitige Erkennen der schweren Reaktionsformen und ihre Behandlung stellen eine große Herausforderung dar. Im Folgenden sollen klinisches Bild, diagnostische Verfahren, differenzialdiagnostische Einordnung, aber auch auslösende Faktoren, pathogenetische Überlegungen und therapeutische Optionen dargestellt werden.

Literatur

• 1 Mockenhaupt M, Norgauer J. Schwere arzneimittelinduzierte Hautreaktionen.  Allergologie. 2001;  9 419-432
• 2 Stevens A M, Johnson F C. A new eruptive fever associated with stomatitis and ophthalmia: Report of two cases in children.  Am J Dis Child. 1922;  4 526-533
• 3 Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin.  Br J Dermatol. 1956;  68 355-361
• 4 Hebra F von. Erythema exsudativum multiforme. In: Atlas der Hautkrankheiten, Kaiserliche Akademie der Wissenschaften. Wien, Austria; 1866: 54-57
• 5 Bastuji-Garin S, Rzany B, Stern R S. et al . Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.  Arch Dermatol. 1993;  129 92-96
• 6 Kauppinen K. Cutaneous reactions to drugs. With special reference to severe bullous mucocutaneous eruptions and sulphonamides. A clinical study.  Acta Derm Venereol Suppl (Stockh) . 1972;  68 1-89
• 7 Mockenhaupt M, Herb T, Liss Y. et al . Generalized bullous fixed drug eruption: analysis of 62 cases. 4th International Drug Hypersensivity Meeting, 22 – 25 April 2010, Rome, Italy.  European Annals of Allergy and Clinical Immunology. 2010;  42 (2) 43
• 8 Salopek T G. Nikolsky’s sign: is it ‘dry’ or is it‘wet’?.  Br J Dermatol. 1997;  136 762-767
• 9 Melish M E, Glasgow L A. The staphylococcal scalded skin syndrome: development of an experimental model.  N Engl J Med. 1970;  282 1114-1119
• 10 Mockenhaupt M, Idzko M, Grosber M. et al . Epidemiology of staphylococcal scalded skin syndrome in Germany.  J Invest Dermatol. 2005;  124 700-703
• 11 Rzany B, Hering O, Mockenhaupt M. et al . Histopathological and epidemiological characteristics of patients with erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Br J Dermatol. 1996;  135 (1) 6-11
• 12 Auquier-Dunant A, Mockenhaupt M, Naldi L. et al . Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis.  Arch Dermatol. 2002;  138 1019-1024
• 13 Ziemer M, Wiesend C L, Vetter R. et al . Cutaneous adverse drug reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.  Arch Dermatol. 2007;  143 711-716
• 14 Sidoroff A, Halevy S, Bouwes Bavinck J N. et al . Acute generalized exanthematous pustulosis (AGEP) – A clinical reaction pattern.  J Cutan Pathol. 2001;  28 113-119
• 15 Bocquet H, Bagot M, Roujeau J C. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS).  Semin Cutan Med Surg. 1996;  15 250-257
• 16 Mockenhaupt M, Viboud C, Dunant A. et al . Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.  J Invest Dermatol. 2008;  128 (1) 35-44
• 17 Halevy S, Ghislain P D, Mockenhaupt M. et al . Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.  J Am Acad Dermatol. 2008;  58 (1) 25-32
• 18 Arzneimittelkommision der Deutschen Ärzteschaft . Allopurinol ist die häufigste Ursache für Stevens-Johnson-Syndrom und Toxisch epidermaler Nekrolyse in Europa und Israel.  Deutsches Ärzteblatt. 2009;  36 1753-1754
• 19 Fagot J P, Mockenhaupt M, Bouwes Bavinck J N. et al . Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis – preliminary results of a case-control study.  AIDS. 2001;  15 1-6
• 20 Dietrich A, Kawakubo Y, Rzany B. et al . Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.  Exp Dermatol. 1995;  4 313-316
• 21 Nassif A, Moslehi H, Le Gouvello S. et al . Evaluation of the potential role of cytokines in toxic epidermal necrolysis.  J Invest Dermatol. 2004;  123 (5) 850-855
• 22 Chung W H, Hung S I, Yang J Y. et al . Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.  Nat Med. 2008;  14 (12) 1343-1350
• 23 Roujeau J C, Huynh T N, Bracq C. et al . Genetic susceptibility to toxic epidermal necrolysis.  Arch Dermatol. 1987;  123 1171-1173
• 24 Chung W H, Hung S I, Hong H S. et al . A marker for Stevens-Johnson syndrome.  Nature. 2004;  428 486
• 25 Lonjou C, Thomas L, Borot N. et al . A marker for Stevens-Johnson-syndrome and toxic epidermal necrolysis: ethnicity matters.  Pharmacogenomics Journal. 2006;  6 265-268
• 26 Hung S I, Chung W H, Liou L B. et al . HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.  Proc Natl Acad Sci USA. 2005;  102 4134-4139
• 27 Lonjou C, Borot N, Sekula P. et al . Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.  Pharmacogenetics and Genomics. 2008;  18 (2) 99-107
• 28 Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: the role of skin-resident T cells.  Curr Opin Allergy Clin Immunol. 2002;  2 (4) 317-323
• 29 Roujeau J C, Chosidow O, Saiag P. et al . Toxic epidermal necrolysis (Lyell's syndrome).  J Am Acad Dermatol. 1991;  23 1039-1058
• 30 Struck M F, Hilbert P, Mockenhaupt M. et al . Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes.  Intensive Care Med. 2009;  36 (1) 22-32
• 31 Gueudry J, Roujeau J C, Binaghi M. et al . Risk factors for the development of ocular complications of Stevens-Johnson syndrome and Toxic epidermal necrolysis.  Arch Dermatol. 2009;  145 (2) 157-162
• 32 Wolkenstein P, Latarje J, Roujeau J. et al . Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.  Lancet. 1998;  352 1586-1589
• 33 Viard I, Wehrli P, Bullani R. et al . Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.  Science. 1998;  282 490-493
• 34 Faye O, Roujeau J C. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIG). Clinical experience to date.  Drugs. 2006;  65 (15) 2085-2090
• 35 Bachot N, Revuz J, Roujeau J C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. A prospective noncomparative study showing no benefit on mortality or progression.  Arch Dermatol. 2003;  139 33-36
• 36 Bastuji-Garin S, Fouchard N, Bertocchi M. et al . SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.  J Invest Dermatol. 2000;  115 149-153
• 37 Schneck J, Fagot J P, Sekula P. et al . Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study.  J Am Acad Dermatol. 2008;  58 (1) 33-40
• 38 Mockenhaupt M. Severe cutaneous adverse reactions. In: Burgdorf WHC, Plewig G, Wolff HH, Landthaler M (Hrsg) Braun-Falco’s Dermatology. 3. Aufl. Heidelberg; Springer 2008: 473-484